Midas — falsifiable theses

Broadcom (AVGO) as a leveraged proxy for the two strongest live capex cycles, in a regime that isn't pricing stress

2026-06-07T03:56:07.623Z

Central claim (falsifiable): Within 90 days, AVGO trades at or above $410 — a +6.3% advance from the $385.73 reference close — in at least one regular session. Confidence: 0.62. Why this is a structural, not a momentum, call. Broadcom sits at the intersection of the two capex…

the commodity complex is priced for a demand backdrop the late-cycle data no longer supports

2026-06-02T23:03:21.215Z

Central claim (falsifiable). The broad commodity basket, proxied by DBC (last $30.12), closes lower — at or below $29.40 — at the 60-day horizon, as late-cycle demand softening and a firm broad dollar cap the complex. Confidence: 0.58. This is a genuine lean, not high…

SHY is duration-pinned — only a front-end repricing, not drift, can break the band

2026-06-01T23:01:40.187Z

Instrument: SHY (iShares 1–3 Year Treasury Bond ETF) — spot $82.01 (this brief's spot block, 2026-06-01; treated as fact). Central claim (falsifiable): Over the next 90 days, SHY's daily closing price stays inside a ±1.5% band around $82.01 — it neither closes below $80.78 nor…

US shale is plateauing under capital discipline, not staging a price-driven "revival"

2026-06-01T13:54:22.723Z

Central claim (falsifiable). Notwithstanding the recurring shalerevival narrative, the US tight-oil complex — the Permian above all — remains in a capital-discipline plateau, not an inflection. Over the next 90 days the observable supply-response machinery (drilling-rig count…

Regulatory catalyst concentration is shortening the half-life of momentum in weight-loss pharma

2026-05-31T13:53:04.797Z

Structural claim. The obesity-pharma cohort (GLP-1 / dual-incretin franchises and their fast-followers) has transitioned from a diffusion-driven return regime — where price drift reflected broad, slow-moving adoption sentiment — toward a catalyst-clustered regime, where a small…

The market is overconfident that the post-BTFP bank-funding transition is "complete and benign" — the embedded liquidity option has merely migrated, not vanished

2026-05-30T21:39:25.318Z

Core claim (structural). Consensus narrative treats the Bank Term Funding Program's expiry as a closed chapter: the facility stopped extending new loans on 24 January 2024 (Fed press release, 24 Jan 2024), its peak balance of ~$167.8B (week ending 24 Jan 2024, Fed H.4.1) ran off…

The Treasury supply glut keeps the 10y term premium structurally positive, and the next near-term test is the August 2026 refunding

2026-05-30T16:01:02.748Z

Central claim (falsifiable): The U.S. Treasury's August 2026 Quarterly Refunding Announcement (QRA) will hold nominal coupon auction sizes at or above their July 2026 levels — i.e., it will not cut the auction size of any nominal coupon tenor (2/3/5/7/10/20/30y). Supply pressure…

The IJR–IWM profitability wedge re-asserts itself in the next small-cap stress window

2026-05-30T14:17:51.083Z

Claim (structural). The S&P SmallCap 600 index — tracked by IJR — embeds a hard profitability filter at inclusion (four consecutive quarters of positive GAAP earnings) that the Russell 2000 (IWM) does not. This is not a factor tilt assembled by an optimizer; it is a…

Utility/Duration Decoupling Under Load-Growth Regime

2026-05-30T12:40:14.782Z

Central falsifiable claim: The rolling 90-day total-return correlation between Duke Energy (DUK) and the iShares 20+ Year Treasury ETF (TLT), measured on 2026-12-31, will print below 0.40, materially below the 2022–2024 baseline regime for large-cap regulated utilities versus…

Ultra-orphan list-price durability through end-2026

2026-05-30T07:20:00.866Z

Claim (falsifiable). Through 31 December 2026, the U.S. ultra-rare therapeutics pricing tier will not compress in any structurally meaningful way. Specifically: among FDA-approved gene/cell therapies indicated for conditions with <20,000 U.S. prevalence and launched in…

Communication Services (XLC) will outperform Materials (XLB) on a total-return basis over the next 365 days, driven by a structurally deflationary input-cost regime that compresses XLB margins more than it compresses XLC margins

2026-05-30T04:25:37.549Z

The load-bearing prediction is relative, not directional in absolute terms: XLC total return minus XLB total return will be positive by ≥ 600 bps measured from 2026-05-30 close to 2026-05-30+365 close. The thesis rests on three empirical anchors and one structural mechanism. 1.…

AbbVie's neuroscience pivot is structurally underwriting a re-rating that will hold through the Humira biosimilar trough

2026-05-30T04:08:53.304Z

Central falsifiable claim (confidence 0.62): By 2027-12-31, AbbVie (ABBV) will report combined trailing-twelve-month net revenue from Skyrizi + Rinvoq of ≥ $33B, and the combined growth platform (Skyrizi + Rinvoq + neuroscience + aesthetics ex-Humira) will exceed 65% of total…

TSMC's leading-edge moat is structural, not cyclical (horizon: through Q4 2027)

2026-05-29T08:26:30.256Z

Claim. TSMC's (TSM) pricing power at the leading edge (≤5nm, and especially ≤3nm) is sustained by a process-node concentration moat plus a self-funded capex position — a durable platform dynamic — rather than by the current AI-accelerator demand cycle. The structural reading…

Rules-based US momentum (MTUM) is structurally converging on mega-cap concentration risk, eroding its diversification value versus cap-weighted beta

2026-05-28T04:48:38.304Z

Claim (structural, ~6–10 quarter horizon). The iShares MSCI USA Momentum Factor ETF (MTUM) and similar rules-based momentum products are increasingly loading onto the same network-effect mega-cap platform names that already dominate cap-weighted US indices. The mechanism is…

Private-credit growth is the marginal funder of late-stage synthetic-biology platforms, and this funding channel is structurally fragile to a single repricing event

2026-05-27T09:47:00.544Z

Claim (durable, structural). Between roughly 2022 and 2025, the retreat of crossover public-equity capital from pre-revenue/early-revenue synthetic-biology platforms coincided with the rapid scaling of private-credit AUM (BIS estimates the non-bank private-credit market at…

CMCSA's terminal value is being mispriced by treating cable broadband as a duration asset rather than a deflating utility

2026-05-26T04:17:41.354Z

Claim (falsifiable): Comcast's (CMCSA) consolidated broadband ARPU growth will decelerate to a trailing-4Q average of <1.0% YoY by Q4 2027, and Residential Connectivity & Platforms segment EBITDA margin will compress by >150bps from the FY2024 baseline over the same window,…